Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Drug Medical Device Policy / Regulatory

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

Fineline Cube Oct 13, 2025

The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...

Company Deals Drug

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Fineline Cube Oct 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...

Company Medical Device

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

Fineline Cube Oct 11, 2025

Peijia Medical Limited (HKG: 9996) announced today that the National Medical Products Administration (NMPA) of...

Company Deals Drug

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Fineline Cube Oct 11, 2025

PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...

Company Deals

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million

Fineline Cube Oct 11, 2025

China‑based Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347) announced that it and its subsidiary Jiaxing...

Company Legal / IP

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

Fineline Cube Oct 11, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...

Company Drug Policy / Regulatory

National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai

Fineline Cube Oct 11, 2025

The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...

Company Deals

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin

Fineline Cube Oct 10, 2025

Novo Nordisk A/S (NYSE: NVO) announced today that it will acquire Akero Therapeutics (NASDAQ: AKRO) for...

Company Drug

Xingqi Pharma Secures NMPA Approval for SQ‑129, a Novel Treatment for Diabetic Macular Edema

Fineline Cube Oct 10, 2025

China‑based Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced today that the China National Medical...

Company Drug

Shanghai Henlius Biotech Achieves Primary Endpoint in Phase 3 Trial of Serplulimab for Early‑Stage Gastric Cancer

Fineline Cube Oct 10, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) today announced that its phase 3, randomized, double‑blind, multi‑center study...

Company Drug

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

Fineline Cube Oct 10, 2025

JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...

Company Medical Device

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Fineline Cube Oct 10, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced on October 7, 2025 that its Endovenous Radiofrequency Ablation System...

Company Drug

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Fineline Cube Oct 10, 2025

Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...

Company Drug

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Fineline Cube Oct 10, 2025

China‑based Huadong Medicine Co., Ltd. (SHE: 000963) announced that its novel antibody‑drug conjugate (ADC), HDM2017...

Company Deals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Fineline Cube Oct 10, 2025

Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine...

Company

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Fineline Cube Oct 10, 2025

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...

Company Medical Device

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Fineline Cube Oct 9, 2025

Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in‑vitro diagnostic (IVD) test, GASTROClear,...

Company Medical Device

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Fineline Cube Oct 9, 2025

Jenscare Scientific Co., Ltd (HKG: 9877) announced that its LuX‑Valve Plus transjugular tricuspid valve replacement...

Company Drug

Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC

Fineline Cube Oct 9, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...

Company Drug

Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub

Fineline Cube Oct 9, 2025

Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...

Posts pagination

1 … 139 140 141 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.